Moreover, tRF-60:76-Val-AAC-1-M5 might target Tnfrsf10b and Bcl2l1 to influence this therapeutic heterogeneity through the lipid and atherosclerosis signaling pathway. This evidence concerns the gene TNFRSF10B and atherosclerosis.